Potential Alzheimer's Drug Target: BDNF-AS (G497258)

Target Name: BDNF-AS

NCBI ID: G497258

BDNF-AS

Potential Alzheimer's Drug Target: BDNF-AS

BDNF-AS, or BDNF-AS-400, is a protein that is expressed in the brain and is known for its role in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is a member of the brain-derived neurotrophic factor (BDNF) family, which is known for its role in the survival and growth of neurons.

Recent studies have identified BDNF-AS as a potential drug target for the treatment of Alzheimer's disease and other neurological disorders. This is because the protein is known to play a role in the formation of neuroplastic structures in the brain, which are thought to be important for the development of the disease. Additionally, BDNF-AS has been shown to be involved in the regulation of several key genes that are involved in the development of neurological disorders, including those that are associated with neurodegeneration.

One of the ways that BDNF-AS is thought to contribute to the development of Alzheimer's disease is by promoting the formation of beta-amyloid plaques, which are thought to be a hallmark of the disease. Beta-amyloid plaques are composed of abnormal aggregates of the protein beta-amyloid, which are thought to play a role in the formation of neuroplastic structures in the brain and the development of Alzheimer's disease.

Another way that BDNF-AS is thought to contribute to the development of Alzheimer's disease is by promoting the growth of neural stem cells. Neural stem cells are a type of cell that have the ability to develop into any type of brain cell, and are thought to play a key role in the development and maintenance of the brain. Studies have shown that BDNF-AS can induce neural stem cells to divide and differentiate into functional neurons, which may be important for the development of the disease.

In addition to its role in the development of Alzheimer's disease, BDNF-AS is also thought to be involved in the regulation of several other genes that are involved in the development and progression of neurological disorders. For example, studies have shown that BDNF-AS can inhibit the activity of the gene APP, which is thought to play a key role in the development of Alzheimer's disease. Additionally, BDNF-AS has been shown to be involved in the regulation of the gene TrkB, which is thought to play a key role in the development of Parkinson's disease.

Given its involvement in the development and progression of Alzheimer's disease, BDNF-AS is a potential drug target for the treatment of the disease. Studies have shown that BDNF-AS can be targeted with small molecules, such as those that inhibit its activity or that activate its activity. Additionally, researchers are also exploring the use of antibodies, which are proteins that can bind to BDNF-AS and prevent it from interacting with its targets, as a potential treatment for the disease.

In conclusion, BDNF-AS is a protein that is expressed in the brain and is known for its role in the development and progression of several neurological disorders. Recent studies have identified BDNF-AS as a potential drug target for the treatment of Alzheimer's disease and other neurological disorders. This is because the protein is known to play a role in the formation of neuroplastic structures in the brain and is involved in the regulation of several key genes that are involved in the development and progression of the disease. Further research is needed to fully understand the role of BDNF-AS as a drug target and to develop effective treatments for the disease.

Protein Name: BDNF Antisense RNA

The "BDNF-AS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BDNF-AS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets